Oncolytic herpes simplex viral therapy: A stride toward selective targeting of cancer cells

Frontiers in Pharmacology

Volumn 8, Issue MAY, 2017, Pages

  Sanchala, Dhaval S ^a   Bhatt, Lokesh K ^a   Prabhavalkar, Kedar S ^a  

^a SVKM S DR BHANUBEN NANAVATI COLLEGE OF PHARMACY   (India)

Author keywords

Cancer; Genetic arming; Herpes simplex virus; Oncolytic viral therapy; Retargeted oncolytic herpes simplex virus 1

Indexed keywords

BCG VACCINE; CG 0070; HISTONE DEACETYLASE INHIBITOR; LOSARTAN; ONCOLYTIC HERPES VIRUS; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CHELATION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TARGETING; GENE DELETION; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LYMPHOMA; METASTATIC MELANOMA; MICROBUBBLE; MOUTH SQUAMOUS CELL CARCINOMA; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; SHORT SURVEY; STOMACH CARCINOMA; SUICIDE GENE THERAPY; TRANSGENE; TUMOR IMMUNITY; ULTRASOUND; VIRUS GENOME; VIRUS REPLICATION;

EID: 85019651565     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00270     Document Type: Short Survey

References (69)

1. Anderson, D. B., Laquerre, S., Ghosh, K., Ghosh, H. P., Goins, W. F., Cohen, J. B., et al. (2000). Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol. 74, 2481-2487. doi: 10.1128/JVI.74.5.2481-2487.2000
2. Baek, H., Uchida, H., Jun, K., Kim, J.-H., Kuroki, M., Cohen, J. B., et al. (2011). Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol. Ther. 19, 507-514. doi: 10.1038/mt.2010.207
3. Burke, J. M. (2010). GM-CSF-armed, replication-competent viruses for cancer. Cytokine Growth Factor Rev. 21, 149-151. doi: 10.1016/j.cytogfr.2010.02.002
4. Burton, E. A., Fink, D. J., and Glorioso, J. C. (2002). Gene delivery using herpes simplex virus vectors. DNA Cell Biol. 21, 915-936. doi: 10.1089/104454902762053864
5. Chang, H.-M., Paulson, M., Holko, M., Rice, C., Williams, B., Marie, I., et al. (2004). Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U.S.A. 101, 9578-9583. doi: 10.1073/pnas.0400567101
6. Chiocca, E. A., Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887. doi: 10.1038/11320
7. Clewell, A., Barnes, M., Endres, J., Ahmed, M., and Ghambeer, D. (2012). Efficacy and tolerability assessment of topical formulation containing copper sulfate and hypericum perforatum on patients with herpes skin lesions: a comparative, randomized controlled trial. J. Drugs Dermatol. 11, 209-215
8. Coffey, M. C., and Thompson, B. G. (2002). Method for Optimally Delivering Virus to a Solid Tumor Mass. U.S. Patent No. 20020061298 A1. Washington, DC: U.S. Patent and Trademark Office
9. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., and Jain, R. K. (2011). Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909-2914. doi: 10.1073/pnas.1018892108
10. Dooley, D. A., Child, Z., Carstensen, E. L., and Miller, M. W. (1983). The effects of continuous wave and pulsed ultrasound on rat thymocytes in vitro. Ultrasound Med. Biol. 9, 379-384. doi: 10.1016/0301-5629(83)90091-1
11. Eager, R. M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317. doi: 10.1038/cgt.2011.7
12. Fechheimer, M., Boylan, J. F., Parker, S., Sisken, J. E., Patel, G. L., and Zimmer, S. G. (1987). Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc. Natl. Acad. Sci. U.S.A. 84, 8463-8467. doi: 10.1073/pnas.84.23.8463
13. Federoff, H. J., Halterman, M. W., and Brooks, A. (1997). Use of the herpes amplicon system as a vehicle for somatic gene transfer. Adv. Drug Deliv. Rev. 27, 29-39. doi: 10.1016/S0169-409X(97)00020-3
14. Fraefell, C., Jacoby, D. R., and Breakefield, X. O. (2000). Herpes simplex virus type 1-based amplicon vector systems. Adv. Virus Res. 55, 425-451. doi: 10.1016/S0065-3527(00)55011-8
15. Goins, W. F., Hall, B., Cohen, J. B., and Glorioso, J. C. (2016). Retargeting of herpes simplex virus (HSV) vectors. Curr. Opin. Virol. 21, 93-101. doi: 10.1016/j.coviro.2016.08.007
16. Herold, B. C., Visalli, R. J., Susmarski, N., Brandt, C. R., and Spear, P. G. (1994). Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J. Gen. Virol. 75, 1211-1222. doi: 10.1099/0022-1317-75-6-1211
17. Herold, B. C., WuDunn, D., Soltys, N., and Spear, P. G. (1991). Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J. Virol. 65, 1090-1098
18. Hu, G. F. (1998). Copper stimulates proliferation of human endothelial cells under culture. J. Cell. Biochem. 69, 326-335. doi: 10.1002/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A
19. Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737-6747. doi: 10.1158/1078-0432.CCR-06-0759
20. Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887. doi: 10.1038/11320
21. Ikeda, K., Wakimoto, H., Ichikawa, T., Jhung, S., Hochberg, F. H., Louis, D. N., et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74, 4765-4775. doi: 10.1128/JVI.74.10.4765-4775.2000
22. Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12, 643-652. doi: 10.1158/1078-0432.CCR-05-1494
23. Jacobs, A., Tjuvajev, J. G., Dubrovin, M., Akhurst, T., Balatoni, J., Beattie, B., et al. (2001). Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo positron emission tomography-based imaging of transgene expression mediated by replication. Cancer Res. 61, 2983-2995
24. Kasuya, H., Nishiyama, Y., Nomoto, S., Hosono, J., Takeda, S., and Nakao, A. (1999). Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J. Surg. Oncol. 72, 136-141. doi: 10.1002/(SICI)1096-9098(199911)72:3<136::AID-JSO5>3.0.CO;2-3
25. Kaufmann, B. A., Lindner, J. R., Wu, J. C., and Narula, J. (2007). Molecular imaging with targeted contrast ultrasound This review comes from a themed issue on analytical biotechnology edited. Curr. Opin. Biotechnol. 18, 11-16. doi: 10.1016/j.copbio.2007.01.004
26. Kelly, E., and Russell, S. J. (2007). History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659. doi: 10.1038/sj.mt.6300108
27. Leoni, V., Gatta, V., Palladini, A., Nicoletti, G., Ranieri, D., Dall'Ora, M., et al. (2015). Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget 6, 34774-34787. doi: 10.18632/oncotarget.5793
28. Lindner, J. R. (2004). Molecular imaging with contrast ultrasound and targeted microbubbles. J. Nucl. Cardiol. 11, 215-221. doi: 10.1016/j.nuclcard.2004.01.003
29. Link, C. J., Hellrung, D. J., Seregina, T., and Wang, S. (2000). Eliciting hyperacute rejection as a tumor killing strategy. Herpes amplicon vector transfer of the a(1, 3)galactosyltransferase gene. Adv. Exp. Med. Biol. 465, 217-227. doi: 10.1007/0-306-46817-4_20
30. Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., et al. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292-303. doi: 10.1038/sj.gt.3301885
31. MacTavish, H., Diallo, J. S., Huang, B., Stanford, M., Le Boeuf, F., De Silva, N., et al. (2010). Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE 5:e14462. doi: 10.1371/journal.pone.0014462
32. Mahller, Y. Y., Vaikunth, S. S., Ripberger, M. C., Baird, W. H., Saeki, Y., Cancelas, J. A., et al. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 68, 1170-1179. doi: 10.1158/0008-5472.CAN-07-2734
33. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., Martuza, R. L., Malick, A. M. Y., et al. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Am. Assoc. Adv. Sc. Stable 252, 854-856
34. Mavani, H., and Wick, J. (2016). Oncology's Trojan horse: using viruses to battle cancer. Consult. Pharm. 31, 676-684. doi: 10.4140/TCP.n.2016.676
35. McKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66, 2509-2513. doi: 10.1158/0008-5472.CAN-05-2242
36. Melcher, A., Parato, K., Rooney, C. M., and Bell, J. C. (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 19, 1008-1016. doi: 10.1038/mt.2011.65
37. Mineta, T., Rabkin, S. D., and Martuza, R. L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966
38. Mocarski, E. S., and Roizman, B. (1982). Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA. Cell 31, 89-97. doi: 10.1016/0092-8674(82)90408-1
39. Munguia, A., Ota, T., Miest, T., and Russell, S. J. (2008). Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 15, 797-806. doi: 10.1038/gt.2008.45
40. Nguyên, T. L.-A., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.-S., et al. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U.S.A. 105, 14981-14986. doi: 10.1073/pnas.0803988105
41. Otsuki, A., Patel, A., Kasai, K., Suzuki, M., Kurozumi, K., Chiocca, E. A., et al. (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16, 1546-1555. doi: 10.1038/mt.2008.155
42. Panteva, M., Varadinova, T., and Turel, I. (1998). Effect of copper acyclovir complexes on herpes simplex virus type 1 and type 2 (HSV-1, HSV-2) infection in cultured cells. Met. Based Drugs 5, 19-23. doi: 10.1155/MBD.1998.19
43. Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533-542. doi: 10.1016/S1470-2045(08)70107-4
44. Passer, B. J., Cheema, T., Zhou, B., Wakimoto, H., Zaupa, C., Razmjoo, M., et al. (2010). Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 70, 3890-3895. doi: 10.1158/0008-5472.CAN-10-0155
45. Pawlik, T. M., Nakamura, H., Yoon, S. S., Mullen, J. T., Chandrasekhar, S., Chiocca, E. A., et al. (2000). Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. 60, 2790-2795
46. Russell, S. J., and Peng, K. W. (2008). The utility of cells as vehicles for oncolytic virus therapies. Curr. Opin. Mol. Ther. 10, 380-386
47. Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., et al. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther. 14, 425-433. doi: 10.1089/104303403321467199
48. Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771. doi: 10.1200/JCO.2009.24.3675
49. Shen, Y., and Nemunaitis, J. (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 13, 975-992. doi: 10.1038/sj.cgt.7700946
50. Shintani, M., Takahashi, G., Hamada, M., Okunaga, S., Iwai, S., and Yura, Y. (2011). Effect of ultrasound on herpes simplex virus infection in cell culture. Virol. J. 8:446. doi: 10.1186/1743-422X-8-446
51. Shishkov, S., Varadinova, T., Panteva, M., and Bontchev, P. (1997). Effect of complexes of zinc, cobalt and copper with d-aminosugars on the replication of herpes simplex virus type 1 (HSV-1). Met. Based Drugs 4, 35-38. doi: 10.1155/MBD.1997.35
52. Soncin, F., Guitton, J. D., Cartwright, T., and Badet, J. (1997). Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem. Biophys. Res. Commun. 236, 604-610. doi: 10.1006/bbrc.1997.7018
53. Spear, P. G. (2004). Herpes simplex virus: receptors and ligands for cell entry. Cell. Microbiol. 6, 401-410. doi: 10.1111/j.1462-5822.2004.00389.x
54. Spear, P. G., Shieh, M. T., Herold, B. C., WuDunn, D., and Koshy, T. I. (1992). Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv. Exp. Med. Biol. 313, 341-353. doi: 10.1007/978-1-4899-2444-5_33
55. Tang, J., Yang, T., Ghosh, H. P., and Geller, A. I. (2001). Helper virus-free HSV-1 vectors packaged both in the presence of VSV G protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum. J. Neurovirol. 7, 548-555. doi: 10.1080/135502801753248132
56. Todo, T. (2008). "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh. Migr. 2, 208-213. doi: 10.4161/cam.2.3.6353
57. Turecký, L., Kalina, P., Uhlíková, E., Námerová, S., and Križko, J. (1984). Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin. Wochenschr. 62, 187-189. doi: 10.1007/BF01731643
58. Tyminski, E., LeRoy, S., Terada, K., Finkelstein, D. M., Hyatt, J. L., Danks, M. K., et al. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 65, 6850-6857. doi: 10.1158/0008-5472.CAN-05-0154
59. Wakimoto, H., Fulci, G., Tyminski, E., and Chiocca, E. A. (2004). Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. 11, 214-223. doi: 10.1038/sj.gt.3302143
60. Wakimoto, H., Ikeda, K., Abe, T., Ichikawa, T., Hochberg, F. H., Ezekowitz, R. A. B., et al. (2002). The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275-282. doi: 10.1006/mthe.2002.0547
61. Wang, Y., and Yuan, F. (2006). Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Ann. Biomed. Eng. 34, 114-127. doi: 10.1007/s10439-005-9007-2
62. Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A., and Vile, R. (2009). Cell carriers for oncolytic viruses: fed Ex for cancer therapy. Mol. Ther. 17, 1667-1676. doi: 10.1038/mt.2009.194
63. Workenhe, S. T., Simmons, G., Pol, J. G., Lichty, B. D., Halford, W. P., and Mossman, K. L. (2014). Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol. Ther. 22, 123-131. doi: 10.1038/mt.2013.238
64. Yamamoto, S., Deckter, L. A., Kasai, K., Chiocca, E. A., and Saeki, Y. (2006). Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther. 13, 1731-1736. doi: 10.1038/sj.gt.3302831
65. Yin, L., Zhao, C., Han, J., Li, Z., Zhen, Y., Xiao, R., et al. (2017). Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther. Clin. Risk Manag. 13, 117-130. doi: 10.2147/TCRM.S128575
66. Yoo, J. Y., Pradarelli, J., Haseley, A., Wojton, J., Kaka, A., Bratasz, A., et al. (2012). Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin. Cancer Res. 18, 4931-4941. doi: 10.1158/1078-0432.CCR-12-0697
67. Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A., and Tanabe, K. K. (2000). An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 14, 301-311
68. Yun, C.-O. (2008). Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther. 10, 356-361
69. Zhou, Z. H., Chen, D. H., Jakana, J., Rixon, F. J., and Chiu, W. (1999). Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. J. Virol. 73, 3210-3218